SCHEMBL752900

SCHEMBL752900

COC(=O)c1ccnc(NC(=O)c2ccc([C@@H](C)[C@@](O)(c3ccnc(Cl)c3)C(F)(F)F)c(Cl)c2)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDK1 Q15118 2/20 0.39
PDK2 Q15119 2/20 0.39
PDK3 Q15120 2/20 0.39
PDK4 Q16654 2/20 0.39
SCN9A Q15858 1/20 0.39
PHGDH O43175 1/20 0.38
BTK Q06187 6/20 0.37
MAPT P10636 3/20 0.36
GSK3B P49841 2/20 0.36
ACLY P53396 1/20 0.36
NTRK1 P04629 1/20 0.36
KMT2A Q03164 2/20 0.36
MEN1 O00255 1/20 0.36
LMNA P02545 1/20 0.36
NPC1 O15118 2/20 0.36
RAB9A P51151 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
PKM P14618 1/20 0.36
TP53 P04637 1/20 0.36
CYP1A2 P05177 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL479642 1.00 PDK1 (0.39) PDK1PDK2PDK3PDK4SCN9A
SCHEMBL479868 0.91 BTK (0.38) PDK1PDK2PDK3PDK4SCN9A
SCHEMBL752907 0.91 BTK (0.38) PDK1PDK2PDK3PDK4SCN9A
SCHEMBL480160 0.91 PDK1 (0.43) PDK1PDK2PDK3PDK4SMN1; SMN2
SCHEMBL480861 0.90 MAPT (0.44) PDK1PDK2PDK3PDK4MAPT
SCHEMBL479972 0.88 RAB9A (0.50) MAPTKMT2AMEN1NPC1RAB9A
SCHEMBL754762 0.88 RAB9A (0.50) MAPTKMT2AMEN1NPC1RAB9A
SCHEMBL480256 0.87 GRM5 (0.38) BTKMAPTKMT2AMEN1LMNA
SCHEMBL479943 0.86 MAPT (0.40) PDK1PDK2PDK3PDK4MAPT
SCHEMBL479727 0.85 RAB9A (0.42) MAPTKMT2AMEN1LMNANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8138189-B2 Substituted benzene compounds as modulators of the glucocorticoid receptor HOFFMAN-LA ROCHE INC. (US) 2012-03-20 US disclosed
US-8138189-B2 Substituted benzene compounds as modulators of the glucocorticoid receptor HOFFMAN-LA ROCHE INC. (US) 2012-03-20 US disclosed
US-20100249139-A1 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS HOFFMANN-LA ROCHE, INC. 2010-09-30 US disclosed
US-20100249139-A1 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS HOFFMANN-LA ROCHE, INC. 2010-09-30 US disclosed
WO-2010108902-A1 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2010-09-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249139-A1 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS NR3C1, NR3C2, CRHR1 PDK1 541/4885PDK2 936/4885PDK3 1054/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.